Sponsored by
This is Dr Patrick Wen's thoughts on the CheckMate-548 study. Dr. Wen is one of the brightest doctors in the field and I highly value his opinions. His conclusion: for Glioblastomas, newly diagnosed or recurrent, with or without MGMT methylation, and regardless of PD-L1 expression, adding nivolumab (Opdivo) to Temodar (and radiation for newly diagnosed) resulted in no improvement. He thinks the path forward is to add in another treatment that makes the tumor susceptible to the checkpoint inhibitors. I agree completely.